{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:47:44Z","timestamp":1784382464077,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We previously identified <jats:italic>Bordetella pertussis<\/jats:italic>-derived outer membrane vesicles (OMVs) as a promising immunogen for improving pertussis vaccines. In this study, we evaluated the efficacy of our vaccine prototype in immunization strategies aimed at reducing disease transmission by targeting colonization in the upper airways while maintaining protection against severe disease by reducing colonization in the lower respiratory tract.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed different mucosal administration strategies in a murine model, including homologous mucosal 2-dose prime-boost schedules and heterologous prime-boost strategies combining intramuscular (IM) systemic immunization with mucosal routes (intranasal, IN; or sublingual, SL). We utilized alum and c-di-AMP as adjuvants for the systemic and mucosal formulations of the OMV vaccine prototype, respectively. A homologous prime\/boost IM immunization schedule and commercial vaccines were used for comparisons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All tested heterologous schemes induced higher levels of specific IgG with significant avidity, as well as higher levels of IgG1 and IgG2c, compared to the corresponding homologous prime-boost 2-dose schemes via mucosal routes (OMV<jats:sub>IN-IN<\/jats:sub> or OMV<jats:sub>SL-SL<\/jats:sub>). High IgA levels were observed post-<jats:italic>B. pertussis<\/jats:italic> challenge following OMV<jats:sub>IN-IN<\/jats:sub> treatments and heterologous treatments where the second dose was administered via a mucosal route (prime-pull scheme). Furthermore, schemes involving the intranasal route, whether in a homologous or heterologous scheme, induced the highest levels of IL-17 and IFN-\u03b3. Accordingly, these schemes showed superior efficacy against nasal colonization than the commercial vaccines. Homologous intranasal immunization exhibited the highest protective capacity against nasal colonization while maintaining an excellent level of protection in the lower respiratory tract. To further enhance protection against nasal colonization, we performed a comparative analysis of formulations containing either single or combined adjuvants, administered via homologous intranasal route. These assays revealed that the use of alum combined with c-di-AMP, did not enhance the immune protective capacity in comparison with that observed for the formulation containing c-di-AMP alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>All the experiments presented here demonstrate that the use of OMVs, regardless of the scheme applied (except for OMV<jats:sub>SL-SL<\/jats:sub>), significantly outperformed acellular pertussis (aP) vaccines, achieving a higher reduction in bacterial colonization in the upper respiratory tract (p&amp;lt;0.01).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1506638","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T13:53:59Z","timestamp":1732802039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Mucosal vaccination with outer membrane vesicles derived from Bordetella pertussis reduces nasal bacterial colonization after experimental infection"],"prefix":"10.3389","volume":"15","author":[{"given":"E.","family":"Rudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bottero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ebensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hozbor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0236041","DOI":"10.1371\/journal.pone.0236041","article-title":"A data driven clinical algorithm for differential diagnosis of pertussis and other respiratory infections in infants","volume":"15","author":"Tozzi","year":"2020","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.65.12.4904-4908.1997","article-title":"Role of gamma interferon in natural clearance of Bordetella pertussis infection","volume":"65","author":"Barbic","year":"1997","journal-title":"Infect Immun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-39-3-163","article-title":"Cellular immunity in pertussis","volume":"39","author":"Mills","year":"1993","journal-title":"J Med Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/mi.2012.54","article-title":"Immunity to the respiratory pathogen Bordetella pertussis","volume":"5","author":"Higgs","year":"2012","journal-title":"Mucosal Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/biol.1999.0183","article-title":"The immunology of Bordetella pertussis infection","volume":"27","author":"Mills","year":"1999","journal-title":"Biologicals"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314688110","article-title":"Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model","volume":"111","author":"Warfel","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/INFDIS\/JIX254","article-title":"Live attenuated pertussis vaccine BPZE1 protects baboons against bordetella pertussis disease and infection","volume":"216","author":"Locht","year":"2017","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femspd\/ftv067","article-title":"Roads to the development of improved pertussis vaccines paved by immunology","volume":"73","author":"Brummelman","year":"2015"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2018.1564630","article-title":"Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis","volume":"8","author":"Wilk","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90061-8","article-title":"Development of a pertussis component vaccine in Japan","volume":"323","author":"Sato","year":"1984","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.24.3003","article-title":"Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults","volume":"293","author":"Pichichero","year":"2005","journal-title":"J Am Med Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00173-7","article-title":"Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602083340602","article-title":"A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine","volume":"334","author":"Gustafsson","year":"1996","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000795","article-title":"Pertussis across the globe: recent epidemiologic trends from 2000 to 2013","volume":"34","author":"Tan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu001","article-title":"Changing pertussis epidemiology: Everything old is new again","volume":"209","author":"Clark","year":"2014","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0665-8","article-title":"Investigating the pertussis resurgence in England and Wales, and options for future control","volume":"14","author":"Choi","year":"2016","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000177282.53500.77","article-title":"Resurgence of pertussis in europe","volume":"24","author":"Celentano","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3973","article-title":"Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis","volume":"137","author":"Breakwell","year":"2016","journal-title":"Pediatrics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3201\/eid2706.203850","article-title":"Pertactin-deficient bordetella pertussis, vaccine-driven evolution, and reemergence of pertussis","volume":"27","author":"Ma","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268813000071","article-title":"Pertussis resurgence: Waning immunity and pathogen adaptation - Two sides of the same coin","volume":"142","author":"Mooi","year":"2014","journal-title":"Epidemiol Infect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001804","article-title":"Resurgence of pertussis and emergence of the ptx p3 toxin promoter allele in south Italy","volume":"37","author":"Loconsole","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/J.MEEGID.2016.02.032","article-title":"Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence","volume":"40","author":"Sealey","year":"2016","journal-title":"Infection Genet Evol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3201\/eid0707.017708","article-title":"Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence","volume":"7","author":"Mooi","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2217\/17460913.3.3.329","article-title":"Factors contributing to pertussis resurgence","volume":"3","author":"He","year":"2008","journal-title":"Future Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1542\/PEDS.2016-4091","article-title":"Effectiveness of vaccination during pregnancy to prevent infant pertussis","volume":"139","author":"Baxter","year":"2017","journal-title":"Pediatrics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000829","article-title":"Review of vaccination in pregnancy to prevent pertussis in early infancy","volume":"67","author":"Campbell","year":"2018","journal-title":"J Med Microbiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.109","article-title":"Maternal immunization in Argentina: A storyline from the prospective of a middle income country","volume":"33","author":"Vizzotti","year":"2015","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES10121990","article-title":"Vaccination in pregnancy against pertussis: A consensus statement on behalf of the global pertussis initiative","volume":"10","author":"Abu-Raya","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/J.COI.2023.102355","article-title":"Nasal vaccines for pertussis","volume":"84","author":"Schmitt","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8040621","article-title":"Next-generation pertussis vaccines based on the induction of protective t cells in the respiratory tract","volume":"8","author":"Chasaide","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-016-0043-8","article-title":"The Pertussis resurgence: Putting together the pieces of the\u00a0puzzle","volume":"2","author":"Lapidot","year":"2016","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12916-015-0382-8","article-title":"Asymptomatic transmission and the resurgence of Bordetella pertussis","volume":"13","author":"Althouse","year":"2015","journal-title":"BMC Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/MI.2014.93","article-title":"A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine","volume":"8","author":"Dunne","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4161\/HV.22755","article-title":"A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis","volume":"9","author":"Asokanathan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0080-x","article-title":"Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T RM cells","volume":"11","author":"Allen","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2017.1276832","article-title":"Outer membrane vesicles: an attractive candidate for pertussis vaccines","volume-title":"Expert Rev Vaccin","author":"Hozbor","year":"2017"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00125","article-title":"A\u00a0Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory\u00a0CD4 T Cells and Protection against Bordetella pertussis, including Pertactin Deficient Strains","volume":"9","author":"Zurita","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.004","article-title":"Outer membrane vesicles as acellular vaccine against pertussis","volume":"26","author":"Roberts","year":"2008","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01879","article-title":"Canonical and non-canonical inflammasome activation by outer membrane vesicles derived from bordetella pertussis","volume":"11","author":"Elizagaray","year":"2020","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.068","article-title":"Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid a deacylase PagL as a novel acellular vaccine candidate","volume":"29","author":"Asensio","year":"2011","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730434","article-title":"Pertussis vaccine candidate based on outer membrane vesicles derived from biofilm culture","volume":"12","author":"Carriquiriborde","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.079","article-title":"Characterization of the immune response induced by pertussis OMVs-based vaccine","volume":"34","author":"Bottero","year":"2016","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.12.048","article-title":"Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes","volume":"32","author":"Gaillard","year":"2014","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-63998-2","article-title":"Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses","volume":"10","author":"Raeven","year":"2020","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/PL00006801","article-title":"Release of outer membrane vesicles from Bordetella pertussis","volume":"38","author":"Hozbor","year":"1999","journal-title":"Curr Microbiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot102269","article-title":"Bradford assay for determining protein concentration","volume":"2020","author":"Kielkopf","year":"2020","journal-title":"Cold Spring Harb Protoc"},{"key":"B47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1128\/CVI.00342-09","article-title":"Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B neisseria meningitidis vaccines made from lipid A acylation mutants","volume":"17","author":"Stoddard","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00723","article-title":"Use of a neonatal-mouse model to characterize vaccines and strategies for overcoming the high susceptibility and severity of pertussis in early life","volume":"11","author":"Martin Aispuro","year":"2020","journal-title":"Front Microbiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/FMICB.2022.958133","article-title":"The role of bacterial cyclic di-adenosine monophosphate in the host immune response","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Microbiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1009890","article-title":"Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses","volume":"17","author":"Sasaki","year":"2021","journal-title":"PloS Pathog"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387534","article-title":"Outer membrane vesicles derived from Bordetella pertussis are potent adjuvant that drive Th1-biased response","volume":"15","author":"Pschunder","year":"2024","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.0708684105","article-title":"Sublingual vaccination with influenza virus protects mice against lethal viral infection","volume":"105","author":"Song","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0032226","article-title":"Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant","volume":"7","author":"Kim","year":"2012","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.0901144","article-title":"Intranasal immunization promotes th17 immune responses","volume":"183","author":"Zygmunt","year":"2009","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0073-9","article-title":"IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine","volume":"11","author":"Solans","year":"2018","journal-title":"Mucosal Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1506638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T13:54:03Z","timestamp":1732802043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1506638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2024.1506638"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1506638","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1506638"}}